Want to see HK:2500 full AI Analyst Report?
2500 Stock Chart & Stats
HK$2.46
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.46
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$0.94 - HK$3.86
Previous CloseN/A
Volume6.42M
Average Volume (3M)837.04K
Market Cap
HK$471.88M
Enterprise ValueHK$670.90
Total Cash (Recent Filing)HK$280.52M
Total Debt (Recent Filing)HK$216.43M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding441,010,220
10 Day Avg. Volume865,630
30 Day Avg. Volume837,037
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Bulls Say, Bears Say
Bulls Say
Improving LeverageLower leverage reduces balance-sheet pressure and gives the company more flexibility while it works to improve operations. The improvement to a debt-to-equity ratio of about 0.12 suggests financing risk is currently more contained than in prior years, although losses remain a constraint.
Solid Gross MarginsMaintaining solid gross margins indicates that the products can generate meaningful value above direct costs, even though overall expenses remain too high. If revenue stabilizes, this gross-margin base could support operating improvement without requiring a fundamental change to the core product economics.
Focused Structural-heart BusinessA focused portfolio in structural heart interventions gives the company a clearly defined medical-device identity and specialized clinical use case. Its products address valvular heart disease through minimally invasive procedures, supporting a coherent long-term commercial strategy around related technologies.
Bears Say
Sharp Revenue ContractionA sharp revenue decline weakens scale, reduces the ability to absorb fixed operating costs, and makes the path to profitability less credible. The contraction is particularly concerning because it followed only flat-to-modest prior growth, indicating limited recent top-line momentum.
Persistent UnprofitabilityContinuing operating and net losses show that the business has not yet converted its products and gross margin into sustainable earnings. Persistent negative margins can dilute equity value over time and limit the company’s ability to fund expansion internally, even if losses have moderated.
Sustained Cash BurnWeak and inconsistent cash generation creates an ongoing need to manage funding carefully while the company remains loss-making. Negative operating and free cash flow, especially the deterioration in 2025, can increase reliance on external financing and constrain investment in future growth.
Venus Medtech (Hangzhou), Inc. Class H News
2500 FAQ
What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$0.94 and its highest was HK$3.86 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$471.88M.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date is Apr 01, 2027 which is in 192 days.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Aug 31, 2026. The company reported -HK$0.498 earnings per share for the quarter.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
According to Wall Street analysts Venus Medtech (Hangzhou), Inc. Class H’s price is currently Overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.498 in its last earnings report. Following the earnings report the stock price went up 0.5%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venus Medtech (Hangzhou), Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.84%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-24.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
Technical Analysis
MicroPort Scientific
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―